Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)
Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge advises Ambea on the acquisition of Validia

 Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connection with the acquisition of Validia Oy from Invalidiliitto, the Finnish Association for the Disabled, a leading care provider in Finland. Through the acquisition, Ambea establishes a presence in the Finnish market and strengthens its position as the only care provider with operations in the four largest Nordic countries. The purchase price amounts to a total of SEK 1, 382 million.
March 12, 2025

Vinge advises on the sale of Road Rental

 Vinge has advised Sobro and other shareholders in connection with the sale of Road Rental to BUKO Group, a leading European actor within temporary traffic management solutions. This strategic partner will give Road Rental access to a broad international network, strong resources and expertise which will enable continued expansion in Sweden as well as the rest of Scandinavia.
March 12, 2025

Vinge has advised Röko in connection with its listing on Nasdaq Stockholm

 Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.
March 11, 2025